Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
52.8 SEK | -1.12% | -3.30% | +15.66% |
May. 15 | Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu | CI |
May. 02 | Integrum Expands Its Product Offering to the United Kingdom Market | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is in a robust financial situation considering its net cash and margin position.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1335 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.66% | 91.75M | - | ||
-11.65% | 20.97B | B | ||
+7.03% | 19.01B | A | ||
+7.82% | 13.79B | B | ||
-13.57% | 2.16B | - | ||
+4.19% | 1.79B | B+ | ||
+21.84% | 1.5B | D- | ||
+13.72% | 616M | - | ||
0.00% | 411M | - | - | |
+88.70% | 218M | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- INTEG B Stock
- Ratings Integrum AB